Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
58.14 EUR | +0.69% | -0.92% | -0.95% |
May. 02 | DANONE : UBS keeps its Buy rating | ZD |
May. 02 | Danone: acquisition of Functional Formularies | CF |
Sales 2024 * | 27.6B 29.73B | Sales 2025 * | 28.64B 30.85B | Capitalization | 37.06B 39.92B |
---|---|---|---|---|---|
Net income 2024 * | 2.19B 2.36B | Net income 2025 * | 2.36B 2.54B | EV / Sales 2024 * | 1.67 x |
Net Debt 2024 * | 9.11B 9.81B | Net Debt 2025 * | 8.27B 8.91B | EV / Sales 2025 * | 1.58 x |
P/E ratio 2024 * |
16.8
x | P/E ratio 2025 * |
15.7
x | Employees | 88,843 |
Yield 2024 * |
3.71% | Yield 2025 * |
3.91% | Free-Float | 93.12% |
Latest transcript on Danone
1 day | +1.70% | ||
1 week | +0.10% | ||
Current month | +0.10% | ||
1 month | +1.80% | ||
3 months | -5.20% | ||
6 months | +3.31% | ||
Current year | +0.07% |
Managers | Title | Age | Since |
---|---|---|---|
Shane Grant
CEO | Chief Executive Officer | - | 21-03-14 |
Chief Executive Officer | 58 | 21-09-14 | |
Juergen Esser
DFI | Director of Finance/CFO | 53 | 99-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lise Kingo
BRD | Director/Board Member | 62 | 22-11-30 |
Gilles Schnepp
CHM | Chairman | 64 | 20-12-13 |
Géraldine Picaud
BRD | Director/Board Member | 54 | 22-04-25 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.97% | 5 M€ | +4.56% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-06 | 58.14 | +0.69% | 415 701 |
24-05-03 | 57.74 | -2.89% | 1,735,441 |
24-05-02 | 59.46 | +1.36% | 1,419,512 |
24-04-30 | 58.66 | 0.00% | 1,771,950 |
24-04-29 | 58.66 | +0.62% | 1,032,070 |
Real-time Euronext Paris, May 06, 2024 at 06:13 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.07% | 39.92B | |
-4.97% | 266B | |
-3.51% | 93.75B | |
+6.16% | 40.03B | |
+7.31% | 39.47B | |
-18.07% | 29.26B | |
-7.58% | 28.39B | |
+12.84% | 25.04B | |
-5.93% | 23.52B | |
+8.23% | 20.69B |
- Stock Market
- Equities
- BN Stock